Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review

被引:2
|
作者
Hyland, Colby J. [1 ,6 ]
McDowell, Michal J. [2 ]
Bain, Paul A. [3 ]
Huskamp, Haiden A. [4 ]
Busch, Alisa B. [4 ,5 ]
机构
[1] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St, Boston, MA 02114 USA
[3] Harvard Med Sch, Countway Lib Med, 10 Shattuck St, Boston, MA 02115 USA
[4] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA
[5] Harvard Med Sch, McLean Hosp, 115 Mill St, Belmont, MA 02478 USA
[6] 75 Francis St, Boston, MA 02115 USA
关键词
Alcohol use disorder; Primary care; Integrated care; Pharmacotherapy; Naltrexone; SUBSTANCE-ABUSE TREATMENT; CHRONIC DISEASE MANAGEMENT; BEHAVIORAL HEALTH-CARE; MENTAL-HEALTH; BRIEF INTERVENTION; TREATMENT ENGAGEMENT; TREATMENT INITIATION; ADDICTION TREATMENT; COLLABORATIVE CARE; TREATMENT PROGRAM;
D O I
10.1016/j.jsat.2022.108919
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Alcohol use disorder (AUD) represents the most prevalent addiction in the United States. Integration of AUD treatment in primary care settings would expand care access. The objective of this scoping review is to examine models of AUD treatment in primary care that include pharmacotherapy (acamprosate, disulfiram, naltrexone). Methods: The team undertook a search across MEDLINE, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, and Web of Science on May 21, 2021. Eligibility criteria included: patient population >= 18 years old, primary care-based setting, US-based study, presence of an intervention to promote AUD treatment, and prescription of FDA-approved AUD pharmacotherapy. Study design was limited to controlled trials and observational studies. We assessed study bias using a modified Oxford Centre for Evidence-based Medicine Rating Framework quality rating scheme. Results: The qualitative synthesis included forty-seven papers, representing 25 primary studies. Primary study sample sizes ranged from 24 to 830,825 participants and many (44 %) were randomized controlled trials. Most studies (80 %) included a nonpharmacologic intervention for AUD: 56 % with brief intervention, 40 % with motivational interviewing, and 12 % with motivational enhancement therapy. A plurality of studies (48 %) included mixed pharmacologic interventions, with administration of any combination of naltrexone, acampro-sate, and/or disulfiram. Of the 47 total studies included, 68 % assessed care initiation and engagement. Fewer studies (15 %) explored practices surrounding screening for or diagnosing AUD. Outcome measures included receipt of pharmacotherapy and alcohol consumption, which about half of studies included (53 % and 51 %, respectively). Many of these outcomes showed significant findings in favor of integrated care models for AUD. Conclusions: The integration of AUD pharmacotherapy in primary care settings may be associated with improved process and outcome measures of care. Future research should seek to understand the varied experiences across care integration models.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings
    Haley, Sean J.
    Pinsker, Erika A.
    Gerould, Heather
    Wisdom, Jennifer P.
    Hagedorn, Hildi J.
    SUBSTANCE ABUSE, 2019, 40 (04) : 501 - 509
  • [2] Improving access to alcohol use disorder pharmacotherapy and treatment in primary care settings
    Hildi Hagedorn
    Alex Sox-Harris
    Jennifer Wisdom
    Donald Hugh Myrick
    Michael Dawes
    Randall Brown
    Elizabeth Oliva
    Implementation Science, 10 (Suppl 1)
  • [3] Alcohol use disorder pharmacotherapy and treatment in primary care settings: the adapt-PC trial
    Hagedorn, Hildi
    Brown, Randall
    Dawes, Michael
    Dieperink, Eric
    Myrick, Donald
    Oliva, Elizabeth
    Wagner, Todd
    Wisdom, Jennifer
    Harris, Alex
    IMPLEMENTATION SCIENCE, 2017, 13
  • [4] Alcohol use disorder pharmacotherapy and treatment in primary care settings: the adapt-PC trial
    Hagedorn, Hildi
    Brown, Randall
    Dawes, Michael
    Dieperink, Eric
    Myrick, Donald
    Oliva, Elizabeth
    Wagner, Todd
    Wisdom, Jennifer
    Harris, Alex
    IMPLEMENTATION SCIENCE, 2018, 13
  • [5] Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC
    Hildi J. Hagedorn
    Randall Brown
    Michael Dawes
    Eric Dieperink
    Donald Hugh Myrick
    Elizabeth M. Oliva
    Todd H. Wagner
    Jennifer P. Wisdom
    Alex H. S. Harris
    Implementation Science, 11
  • [6] Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC
    Hagedorn, Hildi J.
    Brown, Randall
    Dawes, Michael
    Dieperink, Eric
    Myrick, Donald Hugh
    Oliva, Elizabeth M.
    Wagner, Todd H.
    Wisdom, Jennifer P.
    Harris, Alex H. S.
    IMPLEMENTATION SCIENCE, 2016, 11
  • [7] Integration of Alcohol Use Disorder Interventions in General Health Care Settings in Sub-Saharan Africa: A Scoping Review
    Mushi, Dorothy
    Francis, Joel M.
    Moshiro, Candida
    Hanlon, Charlotte
    Teferra, Solomon
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [8] Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review
    Rombouts, Susan A.
    Conigrave, James H.
    Saitz, Richard
    Louie, Eva
    Haber, Paul
    Morley, Kirsten C.
    BMC FAMILY PRACTICE, 2020, 21 (01)
  • [9] Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review
    Susan A. Rombouts
    James H. Conigrave
    Richard Saitz
    Eva Louie
    Paul Haber
    Kirsten C. Morley
    BMC Family Practice, 21
  • [10] Integration and Sustainability of Alcohol Screening, Brief Intervention, and Pharmacotherapy in Primary Care Settings
    Ornstein, Steven M.
    Miller, Peter M.
    Wessell, Andrea M.
    Jenkins, Ruth G.
    Nemeth, Lynne S.
    Nietert, Paul J.
    JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2013, 74 (04) : 598 - 604